Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

Journal of Cell Biology

Volumn 160, Issue 5, 2003, Pages 781-791

  Czekay, Ralf Peter ^a   Aertgeerts, Kathleen ^a,b   Curriden, Scott A ^a   Loskutoff, David J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Takeda San Diego Inc   (United States)

Author keywords

Endocytosis; Fibronectin; Integrin deactivation; uPAR (CD87); Vitronectin

Indexed keywords

COLLAGEN TYPE 1; INTEGRIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MANGANESE CHLORIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL FRACTIONATION; CELL MIGRATION; CELL STRAIN MCF 7; CELL SURFACE; CHO CELL; CONTROLLED STUDY; ENDOCYTOSIS; EXTRACELLULAR MATRIX; HELA CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL ADHESION; CELL MEMBRANE; CELL MOVEMENT; CHO CELLS; COLLAGEN TYPE I; CRICETINAE; ENDOCYTOSIS; EUKARYOTIC CELLS; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; INTEGRIN ALPHAV; INTEGRINS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 0037416209     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.200208117     Document Type: Article

References (38)

1. Andreasen, P.A., R. Egelund, and H.H. Petersen. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57:25-40.
2. Berkenpas, M.B., D.A. Lawrence, and D. Ginsburg. 1995. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14:2969-2977.
3. Chapman, H.A., and Y. Wei. 2001. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb. Haemost. 86:124-129.
4. Cubellis, M.V., P. Andreasen, P. Ragno, M. Mayer, K. Dano, and F. Blasi. 1989. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA. 86:4828-4832.
5. Czekay, R.P., T.A. Kuemmel, R.A. Orlando, and M.G. Farquhar. 2001. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell. 12:1467-1479.
6. Degryse, B., C.F.M. Sier, M. Resnati, M. Conese, and F. Blasi. 2001. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 505:249-254.
7. Deng, G., S.A. Curriden, S. Wang, S. Rosenberg, and D.J. Loskutoff. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134:1563-1571.
8. Deng, G., S.A. Curriden, G. Hu, R.-P. Czekay, and D.J. Loskutoff. 2001. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain ofvitronect. J. Cell. Physiol. 189:23-33.
9. de Witte, J.H., J.A. Foekens, N. Brunner, J.J. Heuvel, T. van Tienoven, M.P. Look, J.G. Klijn, A. Geurts-Moespot, N. Grebenchtchikov, T. Benraad, et al. 2001. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br. J. Cancer 85:85-92.
10. Dunn, K.W., T.E. McGraw, and F.R. Maxfield. 1989. Iterative fractionation of recycling receptors from lysosomally destined ligands in an early sorting endosome. J. Cell Biol. 109:3303-3314.
11. Foekens, J.A., H.A. Peters, M.P. Look, H. Portengen, M. Schmitt, M.D. Kramer, N. Brunner, F. Janicke, M.E. Meijer-van Gelder, S.C. Henzen-Logmans, et al. 2000. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60:636-643.
12. Fowler, B., N. Mackman, R.J. Parmer, and L.A. Miles. 1998. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR. Thromb. Haemost. 80:148-154.
13. Germer, M., S.M. Kanse, T. Kirkegaard, L. Kjoller, B. Felding-Habermann, S. Goodman, and K.T. Preissner. 1998. Kinetic analysis of integrin-dependent cell adhesion on vitronectin. The inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur. J. Biochem. 253:669-674.
14. Herz, J., J.L. Goldstein, D.K. Strickland, Y.K. Ho, and M.S. Brown. 1991. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-retated protein/alpha 2-macroglobulin receptor. J. Biol. Chem. 266:21232-21238.
15. Huttenlocher, A., R.R. Sandborg, and A.F. Horwitz. 1995. Adhesion in cell migration. Curr. Opin. Cell Biol. 7:697-706.
16. Kjoller, L. 2002. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 383:5-19.
17. Kvassman, J.-O., and J.D. Shore. 1995. Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic interaction chromatography. Fibrinolysis. 9:215-221.
18. Lauffenburger, D.A., and A.F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell. 84:359-369.
19. Lawrence, D.A., M.B. Berkenpas, S. Palaniappan, and D. Ginsburg. 1994. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269:15223-15228.
20. Liu, D., J.A. Ghiso, Y. Estrada, and L. Ossowski. 2002. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 1:445-457.
21. Loskutoff, D.J., S.A. Curriden, G. Hu, and G. Deng. 1999. Regulation of cell adhesion by PAI-1. APMIS. 107:54-61.
22. Mondino, A., M. Resnati, and F. Blasi. 1999. Structure and function of the urokinase receptor. Thromb. Haemost. 82:19-22.
23. Murphy-Ullrich, J.E. 2001. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107:785-790.
24. Nykjær, A., M. Conese, E.I. Christensen, D. Olson, O. Cremona, J. Gliemann, and F. Blasi. 1997. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16:2610-2620.
25. Okumura, Y., Y. Kamikubo, S.A. Curriden, J. Wang, T. Kiwada, S. Futaki, K. Kitagawa, and D.J. Loskutoff. 2002. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J. Biol. Chem. 277:9395-9404.
26. Ossowski, L., and J.A. Aguirre-Ghiso. 2000. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12:613-620.
27. Pampori, N., T. Hato, D.G. Stupack, S. Aidoudi, D.A. Cheresh, G.R. Nemerow, and S.J. Shattil. 1999. Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J. Biol. Chem. 274:21609-21616.
28. Ploug, M., S. Ostergaard, L.B.L. Hansen, A. Holm, and K. Dano. 1998. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry. 37:3612-3622.
29. 3 binding to vitronectin. Nature. 383:441-443.
30. Stefansson, S., E. Petitclerc, M.K. Wong, G.A. McMahon, P.C. Brooks, and D.A. Lawrence. 2001. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1 J. Biol. Chem. 276:8135-8141.
31. Strandberg, L., and E.L. Madison. 1995. Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors. J. Biol. Chem. 270:23444-23449.
32. Tarui, T., A.P. Mazar, D.B. Cines, and Y. Takada. 2001. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J. Biol. Chem. 276:3983-3990.
33. van Meijer, M., and H. Pannekoek. 1995. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis. 9:263-276.
34. Waltz, D.A., L.R. Natkin, R.M. Fujita, Y. Wei, and H.A. Chapman. 1997. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100:58-67.
35. Webb, D.J., K.S. Thomas, and S.L. Gonias. 2001. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J. Cell Biol. 152:741-752.
36. Wei, Y., J.A. Eble, Z. Wang, J.A. Kreidberg, and H.A. Chapman. 2001. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol. Biol. Cell. 12:2975-2986.
37. Yatohgo, T., M. Izumi, H. Kashiwagi, and M. Hayashi. 1988. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct. 13:281-292.
38. Zaffran, Y., S.C. Meyer, E. Negrescu, K.B. Reddy, and J.E. Fox. 2000. Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIb-beta 3 activation both in platelets and a transfected Chinese hamster ovary cell system. J. Biol. Chem. 275:16779-16787.